← Back to Analyst Consensus 
EIKN Buy
Eikon Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Aug 14, 2026 | Wedbush | maintain | Underperform → Underperform | — | 58% |
| May 12, 2026 | Wedbush | maintain | Underperform → Underperform | — | 58% |
| Mar 31, 2026 | Wedbush | reiterate | Underperform → Underperform | — | 58% |
| Mar 2, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Mar 2, 2026 | JP Morgan | initiate | — → Overweight | — | 55% |
| Mar 2, 2026 | B of A Securities | initiate | — → Buy | — | 53% |
| Mar 2, 2026 | Mizuho | initiate | — → Outperform | — | 52% |
| Mar 2, 2026 | Morgan Stanley | initiate | — → Overweight | — | 54% |
| Feb 26, 2026 | Wedbush | initiate | — → Underperform | $7 | 58% |
Price Target Trend
Apr 21, 2026 Oct 26, 2026
EPS Estimates
0y —
0q —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days